Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Nimocal helps improve neurological recovery after a subarachnoid hemorrhage caused by a ruptured berry aneurysm in the brain. It works by lowering the risk and severity of ischemic damage (reduced blood flow to brain tissue) that can follow this type of bleeding. It is used for this purpose regardless of the patient's neurological condition following the initial bleeding episode.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Adult: The initial dose is 60 mg every four hours for 21 consecutive days, preferably taken at least one hour before or two hours after meals. Oral Nimodipine therapy should begin within 96 hours of the subarachnoid hemorrhage. Use in Pediatric Patients: No specific information is available on the use of this medication in pediatric patients.
Side Effects
Side effects with Nimocal are uncommon, but some people may notice headache, dizziness, or flushing (a warm feeling). Others may experience heartburn, an unusually fast or slow heartbeat, an upset stomach, stomach pain, constipation, or low mood, among other possible effects.
Cautions & Contraindications
Warnings & Precautions
Blood pressure: Nimocal produces the hemodynamic effects expected of a calcium channel blocker, though these are generally mild. Blood pressure should be monitored carefully during treatment with Nimocal, in line with its known pharmacology and the effects typical of calcium channel blockers. Hepatic disease: In patients with impaired hepatic function, the metabolism of Nimocal is reduced. These patients should have their blood pressure and pulse rate monitored closely and should be given a lower dose.
Contraindications
Use within 1 month of a heart attack (MI) or an episode of unstable angina. Concomitant use with potent CYP3A4 inhibitors (e.g. clarithromycin, ritonavir, ketoconazole, nefazodone).